Clinical Trials

Eikon Therapeutics adds a consumer goods giant to its board, a move signaling a strategic pivot from pure science to global commercialization.

Kymera Therapeutics' new lupus data isn't just about a drug. It's about a new strategy: erasing disease-causing proteins to build resilient value.

Phenomenex, a Danaher company, launches its Luna Omega HILIC columns, aiming to simplify complex analysis in pharma, food safety, and diagnostics.

Mineralys Therapeutics' Lorundrostat shows promise in reducing heart failure risk, a breakthrough for millions struggling with uncontrolled hypertension.

With a new CMO known for getting drugs approved, Protego Biopharma is betting big on its novel approach to treating a devastating rare disease.

Hong Kong's NatureU touts impressive anti-aging results on a public registry, but a closer look reveals a complex strategy blending early science with savvy marketing.

A small biotech is about to reveal data on a novel drug that could change autoimmune care. Will its bold scientific strategy pay off for patients and investors?

Exigent Research Network's hire of Nina Chavez is more than a personnel move; it's a strategic play to decentralize and democratize cancer research.

Market research shows doctors are eager to prescribe Moleculin's new AML drug, Annamycin. It offers hope where there is none, but can the company survive to deliver it?

Sanofi deepens its partnership with Owkin, licensing its 'K Pro' platform to build autonomous AI agents. A look at the strategy behind this major bet.

Landmark trial results for Bayer's KERENDIA unlock a vast new market in non-diabetic kidney disease, offering hope to millions and a strategic win for the firm.

Interim Phase 3 data shows Otsuka's VOYXACT not only meets surrogate endpoints but preserves kidney function, a strategic masterstroke in the competitive nephrology market.

Beyond the headlines of a new cancer therapy, French biotech Oncovita is executing a masterclass in strategy, leveraging a modified measles virus and AI.

A pharma revolution is brewing for Generalized Anxiety Disorder. As prevalence soars, novel therapies targeting new neural pathways promise to upend the market.

SciSparc's subsidiary just spent nearly C$10M on a quantum computing firm. This is the operational innovation designed to fix billion-dollar clinical trial failures.

With a 'best-in-class' obesity drug and a novel MASH therapy, clinical-stage MetaVia is set to woo investors. Can its science stand out against the giants?

Syndax Pharmaceuticals secures a $250M war chest via convertible notes. We decode the deal, what it means for its cancer drugs, and why it's a savvy move.

Scispot's Series A targets the messy 'coordination gap' in labs. It's a bet that before we get self-driving labs, we must first fix the data pipes.

Barcelona's Ona Therapeutics secures $86.6M to advance its novel antibody-drug conjugates, moving beyond existing treatments to tackle resistant cancers.

Jade Biosciences secures a massive $150M offering to fuel its promising drug pipeline, but the deal's pricing reveals the intense pressures of the biotech market.